blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4098256

EP4098256 - DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.01.2026
Database last updated on 01.04.2026
FormerThe patent has been granted
Status updated on  24.01.2025
FormerGrant of patent is intended
Status updated on  14.01.2025
FormerExamination is in progress
Status updated on  11.11.2022
FormerRequest for examination was made
Status updated on  04.11.2022
Most recent event   Tooltip01.01.2026No opposition filed within time limitpublished on 04.02.2026  [2026/06]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2022/49]
Inventor(s)01 / SCHMOUDER, Robert
East Hanover / US
02 / DUMORTIER, Thomas
Basel / CH
03 / DAVID, Olivier
Basel / CH
04 / LOOBY, Michael
Basel / CH
 [2022/49]
Representative(s)Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
[2022/49]
Application number, filing date22187007.421.12.2009
[2022/49]
Priority number, dateUS20080139672P22.12.2008         Original published format: US 139672 P
US20090218530P19.06.2009         Original published format: US 218530 P
US20090246715P29.09.2009         Original published format: US 246715 P
[2022/49]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP4098256
Date:07.12.2022
Language:EN
[2022/49]
Type: B1 Patent specification 
No.:EP4098256
Date:26.02.2025
Language:EN
[2025/09]
Type: B9 Corrected patent specification 
No.:EP4098256
Date:18.06.2025
[2025/25]
Search report(s)(Supplementary) European search report - dispatched on:EP28.10.2022
ClassificationIPC:A61K31/137, A61P37/00, A61P37/06, A61K31/135, A61K31/138, A61K31/661
[2022/49]
CPC:
A61K31/137 (EP,IL,KR,US); A61K31/135 (EP,IL,US); A61K31/138 (EP,IL,US);
A61K31/661 (EP,IL,US); A61P37/00 (EP,IL,US); A61P37/06 (EP,IL,US);
C07F9/10 (IL,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2023/28]
Former [2022/49]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  SM,  TR 
Extension statesAL02.06.2023
BA02.06.2023
RS02.06.2023
TitleGerman:DOSIERUNGSPLAN FÜR EINEN S1P-REZEPTORAGONISTEN[2022/49]
English:DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST[2022/49]
French:POSOLOGIE D'UN AGONISTE DU RÉCEPTEUR S1P[2022/49]
Examination procedure26.07.2022Examination requested  [2022/49]
28.10.2022Date on which the examining division has become responsible
09.11.2022Despatch of a communication from the examining division (Time limit: M04)
13.01.2023Reply to a communication from the examining division
09.03.2023Despatch of a communication from the examining division (Time limit: M04)
13.03.2023Reply to a communication from the examining division
16.05.2023Despatch of a communication from the examining division (Time limit: M04)
02.06.2023Reply to a communication from the examining division
15.10.2024Date of oral proceedings
28.10.2024Despatch of a communication from the examining division (Time limit: M02)
28.10.2024Minutes of oral proceedings despatched
29.10.2024Reply to a communication from the examining division
15.01.2025Communication of intention to grant the patent
16.01.2025Fee for grant paid
16.01.2025Fee for publishing/printing paid
16.01.2025Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP09797234.3  / EP2379067
EP15158251.7  / EP2907511
EP16182876.9  / EP3120844
EP18201062.9  / EP3453387
EP20160225.7  / EP3677260
Opposition(s)27.11.2025No opposition filed within time limit [2026/06]
Fees paidRenewal fee
26.07.2022Renewal fee patent year 03
26.07.2022Renewal fee patent year 04
26.07.2022Renewal fee patent year 05
26.07.2022Renewal fee patent year 06
26.07.2022Renewal fee patent year 07
26.07.2022Renewal fee patent year 08
26.07.2022Renewal fee patent year 09
26.07.2022Renewal fee patent year 10
26.07.2022Renewal fee patent year 11
26.07.2022Renewal fee patent year 12
26.07.2022Renewal fee patent year 13
29.11.2022Renewal fee patent year 14
29.11.2023Renewal fee patent year 15
27.11.2024Renewal fee patent year 16
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipSM26.02.2025
[2025/46]
Documents cited:Search[Y]   SCHMOULDER R., ET AL.: "Multiple Sclerosis", vol. 14, part Abst P507 17 September 2008, SAGE, London, article ORAL FINGOLIMOD (FTY720), 0.5 OR 1.25 MG, FOR 14 DAYS HAS NO EFFECT ON CARDIAC FUNCTION: "World Congresson Treatment and Research on Multiple Sclerosis", pages: S177, XP009127649
 [Y]   KAPPOS LUDWIG ET AL: "Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis for the FTY720 D2201 Study Group* From the A BS TR AC T", CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS NOVARTIS PHARMACEUTICALS EAST HANOVER NJ (A.A.K.) N ENGL J MED COPYRIGHT MASSACHUSETTS MEDICAL SOCIETY, 1 January 2006 (2006-01-01), pages 1124 - 40, XP055951855, Retrieved from the Internet [retrieved on 20220816]
 [Y]   GRLER MARKUS H. ET AL: "The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G protein-coupled receptors", THE FASEB JOURNAL, vol. 18, no. 3, 8 January 2004 (2004-01-08), US, pages 551 - 553, XP055784240, ISSN: 0892-6638, Retrieved from the Internet [retrieved on 20221020], DOI: 10.1096/fj.03-0910fje

DOI:   http://dx.doi.org/10.1096/fj.03-0910fje
 [Y]   BOON NICHOLAS A: "Davidson's Principles & Practice of Medicine", 1 January 2006 (2006-01-01), Toronto, pages 24 - 25, XP055973444, Retrieved from the Internet [retrieved on 20221020]
by applicantEP0627406
 WO0218395
 WO03097028
   MEHLING MBRINKMANN VANTEL JBAR-OR AGOEBELS NVEDRINE CKRISTOFIC CKUHLE JLINDBERG RLKAPPOS L, NEUROLOGY, vol. 71, no. 16, 14 October 2008 (2008-10-14), pages 1261 - 7
   KAPPOS LANTEL JCOMI GMONTALBAN XO'CONNOR PPOLMAN CHHAAS TKORN AAKARLSSON GRADUE EW: "FTY720 D2201 Study Group", N ENGL J MED, vol. 355, no. 11, 14 September 2006 (2006-09-14), pages 1124 - 40
   ROBERT SCHMOUDERDENISE SERRAYIBIN WANGJOHN M. KOVARIKJOHN DIMARCOTHOMAS L. HUNTMARIE-CLAUDE BASTIEN: "FTY720: Placebo-Controlled Study of the Effect on Cardiac Rate and Rhythm in Healthy Subjects", J. CLIN. PHARMACOL., vol. 46, 2006, pages 895, XP008107801, DOI: 10.1177/0091270006289853

DOI:   http://dx.doi.org/10.1177/0091270006289853
   DS. IM ET AL., MOL. PHARMACOL., vol. 57, 2000, pages 753
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.